FibroGen, Inc. (NASDAQ:FGEN) went up to recover about 28.87% since recording its record low price of $37.27. The stock experienced -8.91% slump, arriving at $48.03 on 4/12/2019. During the day, the stock price traveled from $47.99 to $53.93. This company shares are 48.87% off its target price of $71.5 and the current market capitalization stands at $4.02B. The recent change has given its price a -14.09% deficit over SMA 50 and -29.93% deficit over its 52-week high. The stock witnessed -13.97% declines, 0.73% gains and -3.46% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FGEN’s volatility during a week at 4.9% and during a month it has been found around 3.8%.FibroGen, Inc. (FGEN) Top Holders
Institutional investors currently hold around $2.72 billion or 67% in FGEN stock. Look at its top three institutional owners: Fmr Llc owns $468.78 million in FibroGen, Inc., which represents roughly 11.66% of the company’s market cap and approximately 17.22% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 7,141,519 shares of the stock are valued at $343.01 million. The third largest holder is Blackrock Inc., which currently holds $303.03 million worth of this stock and that ownership represents nearly 7.54% of its market capitalization.
At the end of December reporting period, 119 institutional holders increased their position in FibroGen, Inc. (NASDAQ:FGEN) by some 7,589,536 shares, 84 decreased positions by 7,047,423 and 35 held positions by 42,030,592. That puts total institutional holdings at 56,667,551 shares, according to SEC filings. The stock grabbed 47 new institutional investments totaling 2,934,261 shares while 35 institutional investors sold out their entire positions totaling 4,109,098 shares.FibroGen, Inc. (NASDAQ:FGEN) Insider Trades
Multiple company employees have indulged in significant insider trading. FibroGen, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Schoeneck James A has sold 2,000 shares of FibroGen, Inc. (FGEN) in the trading session dated Apr. 08, 2019. These shares are worth $105,800 and were traded at $52.9 each. The SEC filing shows that Kurkijarvi Kalevi performed a sale of 4,000 shares. The Director disposed these shares by way of transaction on Apr. 08, 2019. The company’s shares were given away at $53.03 per share worth to an income of some $212,120 to the account of Kurkijarvi Kalevi.
CEO, Neff Thomas B, sold 39,636 common shares of FibroGen, Inc. (FGEN) in the open market. In a transaction dated Apr. 04, 2019, the shares were put up for sale at an average price of $54.07, raking in a sum of $2,143,119. After this sale, 2,694,050 common shares of FGEN are directly owned by the insider, with total stake valued at $129,395,222.
In the transaction dated Mar. 21, 2019, a great number of shares sold came courtesy the CEO; Neff Thomas B disposed a total of 39,636 shares at an average price of $55.52, amounting to approximately $2,200,591. The insider now directly owns 2,720,018 shares worth $130,642,465.FibroGen, Inc. (FGEN) Analyst Guide
Several analysts have released their opinion on FibroGen, Inc. (NASDAQ:FGEN), with 5 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.43 average brokerage recommendation [T1].